MMV-supported projects


MMV support to projects may include financial, in-kind, and advisory activities.


Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.

 Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. 

WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.  

Paediatric formulation.

Brand names:

1 Coartem® Dispersible

2 Artesun® 

3 Eurartesim®

4 Pyramax® tablets or granules

5 ASAQ Winthrop® 


7 100mg Artesunate Rectocaps

8 ArtecapTM

9 Kozenis/Krintafel (Trademarks owned or licensed by GSK)

10 Larinate® 60mg 

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure, artemisinin-based combination therapies  

____  Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1

____  Severe malaria treatment and pre-referral intervention

____  Intermittent /seasonal malaria chemoprevention 

____  Products targeting prevention of relapse for P. vivax 

____  Single-exposure chemoprotection (SEC) TPP-2

Target Candidate Profiles- represented by icons

 Asexual blood stages

 Relapse prevention

 Transmission reduction